BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38332855)

  • 21. Impact of Donor and Recipient
    Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
    Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis.
    Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Cui Y
    Curr Drug Metab; 2021; 22(10):758-771. PubMed ID: 34525930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.
    Li Y; Yan L; Shi Y; Bai Y; Tang J; Wang L
    Springerplus; 2015; 4():637. PubMed ID: 26543771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of limited-sampling strategies to calculate AUC
    Galvez C; Boza P; González M; Hormazabal C; Encina M; Azócar M; Castañeda LE; Rojo A; Ceballos ML; Krall P
    Front Pharmacol; 2023; 14():1044050. PubMed ID: 36998611
    [No Abstract]   [Full Text] [Related]  

  • 25. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.
    Wang CB; Zhang YJ; Zhao MM; Zhao L
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110866. PubMed ID: 37678026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients.
    Zhou Y; Huang X; Liu L; Zeng F; Han Y; Zhang J; Zhou H; Zhang Y
    Transpl Immunol; 2023 Feb; 76():101748. PubMed ID: 36423734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients.
    Kim JH; Han N; Kim MG; Kim YW; Jang H; Yun HY; Yu MY; Kim IW; Kim YS; Oh JM
    Sci Rep; 2019 Aug; 9(1):11740. PubMed ID: 31409869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.
    Chen P; Dai R; She Y; Fu Q; Huang M; Chen X; Wang C
    Clin Transplant; 2022 Dec; 36(12):e14807. PubMed ID: 36057787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.
    Hu C; Yin WJ; Li DY; Ding JJ; Zhou LY; Wang JL; Ma RR; Liu K; Zhou G; Zuo XC
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1437-1447. PubMed ID: 30019212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients.
    Zaltzman AS; Glick LA; Zaltzman JS; Nash M; Huang M; Prasad GV
    Transplant Res; 2016; 5():2. PubMed ID: 26823971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
    Wanas H; Kamel MH; William EA; Fayad T; Abdelfattah ME; Elbadawy HM; Mikhael ES
    J Clin Lab Anal; 2023 Oct; 37(19-20):e24969. PubMed ID: 37789683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.
    Maldonado AQ; Asempa T; Hudson S; Rebellato LM
    Pharmacotherapy; 2017 Sep; 37(9):1081-1088. PubMed ID: 28605053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.
    Yoon JG; Song SH; Choi S; Oh J; Jang IJ; Kim YJ; Moon S; Kim BJ; Cho Y; Kim HK; Min S; Ha J; Shin HS; Yang CW; Yoon HE; Yang J; Lee MG; Park JB; Kim MS;
    Transplantation; 2021 Oct; 105(10):2213-2225. PubMed ID: 33654003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant.
    Hannachi I; Ben Fredj N; Chadli Z; Ben Fadhel N; Ben Romdhane H; Touitou Y; Boughattas NA; Chaabane A; Aouam K
    Toxicol Appl Pharmacol; 2020 Jun; 396():115000. PubMed ID: 32275916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
    Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
    Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
    Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
    Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation.
    Rao N; Carcella T; Patel N; Bartlett F; Posadas MA; Casey M; Dubay DA; Taber DJ
    Pharmacogenet Genomics; 2023 Apr; 33(3):59-65. PubMed ID: 36877088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.